Avanos Medical, Inc. $AVNS Position Increased by Prudential Financial Inc.

Prudential Financial Inc. raised its stake in Avanos Medical, Inc. (NYSE:AVNS) by 2.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 382,099 shares of the company’s stock after buying an additional 8,838 shares during the period. Prudential Financial Inc.’s holdings in Avanos Medical were worth $4,677,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. grew its holdings in shares of Avanos Medical by 24.8% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,757,576 shares of the company’s stock worth $53,847,000 after acquiring an additional 746,264 shares during the last quarter. Armistice Capital LLC acquired a new position in shares of Avanos Medical in the 1st quarter valued at $28,660,000. Tributary Capital Management LLC increased its stake in Avanos Medical by 10.0% in the 2nd quarter. Tributary Capital Management LLC now owns 810,720 shares of the company’s stock worth $9,923,000 after purchasing an additional 73,518 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Avanos Medical by 32.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 608,635 shares of the company’s stock worth $8,722,000 after buying an additional 148,619 shares during the period. Finally, Millennium Management LLC raised its holdings in Avanos Medical by 508.3% during the 1st quarter. Millennium Management LLC now owns 547,740 shares of the company’s stock worth $7,849,000 after buying an additional 457,703 shares during the period. Institutional investors and hedge funds own 95.17% of the company’s stock.

Analyst Ratings Changes

AVNS has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Avanos Medical in a report on Tuesday, November 25th. Zacks Research raised shares of Avanos Medical to a “hold” rating in a research note on Tuesday, August 12th. Finally, Wall Street Zen raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Avanos Medical currently has an average rating of “Reduce”.

Avanos Medical Trading Down 0.8%

Shares of NYSE:AVNS opened at $11.74 on Monday. The firm has a fifty day moving average of $11.48 and a two-hundred day moving average of $11.80. The company has a quick ratio of 1.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.12. Avanos Medical, Inc. has a 12-month low of $9.30 and a 12-month high of $19.91. The firm has a market capitalization of $544.97 million, a P/E ratio of -1.15 and a beta of 1.09.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.10. The business had revenue of $177.80 million for the quarter, compared to the consensus estimate of $164.50 million. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. Avanos Medical’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.33 earnings per share. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. On average, equities analysts expect that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.

Insider Buying and Selling at Avanos Medical

In other news, SVP Kerr Holbrook sold 15,000 shares of Avanos Medical stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $11.00, for a total transaction of $165,000.00. Following the completion of the sale, the senior vice president directly owned 83,860 shares in the company, valued at $922,460. The trade was a 15.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.64% of the stock is owned by company insiders.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.